Cargando…
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
c-Maf is a critical oncogenic transcription factor that contributes to myelomagenesis. Our previous studies demonstrated that the deubiquitinase USP5 stabilizes c-Maf and promotes myeloma cell proliferation and survival; therefore, the USP5/c-Maf axis could be a potential target for myeloma therapy....
Autores principales: | Chen, Xue-han, Xu, Yu-jia, Wang, Xiao-ge, Lin, Peng, Cao, Bi-yin, Zeng, Yuan-ying, Wang, Qi, Zhang, Zu-bin, Mao, Xin-liang, Zhang, Tie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468578/ https://www.ncbi.nlm.nih.gov/pubmed/31197245 http://dx.doi.org/10.1038/s41401-019-0249-1 |
Ejemplares similares
-
Liposome-Encapsulated
Melphalan Exhibits Potent Antimyeloma
Activity and Reduced Toxicity
por: Lin, Zhimei, et al.
Publicado: (2022) -
Bisphosphonates as antimyeloma drugs
por: Modi, N D, et al.
Publicado: (2012) -
Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
por: Wang, Siyu, et al.
Publicado: (2017) -
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
por: Harada, Takeshi, et al.
Publicado: (2022) -
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
por: D'Souza, Criselle, et al.
Publicado: (2021)